Dr. Jim Brown, the CEO of DURECT, describes their first Phase 2 clinical trials for Alcoholic Hepatitis Walid Elshahed Dr. Jim Brown, the CEO of DURECT, describes their first Phase 2 clinical trials for Alcoholic Hepatitis Read More »
Get to Know Norman Sussman, Chief Medical Officer at DURECT Walid Elshahed Get to Know Norman Sussman, Chief Medical Officer at DURECT Read More »
VIDEO: New interventions may soon treat alcohol-related hepatitis, expert says Walid Elshahed VIDEO: New interventions may soon treat alcohol-related hepatitis, expert says Read More »
Q&A: DUR-928 ‘well tolerated’ for NASH in Phase 1b study Walid Elshahed Q&A: DUR-928 ‘well tolerated’ for NASH in Phase 1b study Read More »
Advancing Epigenetic Therapies to Treat Liver Diseases with James Brown DVM DURECT Walid Elshahed Advancing Epigenetic Therapies to Treat Liver Diseases with James Brown DVM DURECT Read More »
AASLD: Durect’s alcoholic hepatitis med repairs liver, cuts mortality in phase 2 Walid Elshahed AASLD: Durect’s alcoholic hepatitis med repairs liver, cuts mortality in phase 2 Read More »
Alcoholic hepatitis drug candidate shows ‘life-saving potential’ Walid Elshahed Alcoholic hepatitis drug candidate shows ‘life-saving potential’ Read More »
